FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2770216631> ?p ?o ?g. }

• W2770216631 endingPage "648" @default.
• W2770216631 startingPage "640" @default.
• W2770216631 abstract "To identify the dose of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin in pediatric patients with type 2 diabetes (T2D).Double-blind, randomized, controlled parallel group study comparing linagliptin 1 and 5 mg once daily, with placebo in 39 patients with T2D aged 10 to below 18 years. The primary efficacy endpoint was the change from baseline in glycated hemoglobin (HbA1c) after 12 weeks of treatment. The key pharmacodynamic endpoint was DPP-4 inhibition during steady-state.Compared to placebo, there was a dose-dependent reduction in mean HbA1c of 0.48% and 0.63% with linagliptin 1 and 5 mg, respectively, associated with corresponding declines in mean fasting plasma glucose (FPG) of 5.6 and 34.2 mg/dL. Median DPP-4 inhibition was 38% with linagliptin 1 mg and 79% with linagliptin 5 mg. Geometric mean trough levels of linagliptin were 3.80 and 7.42 nmol/L in the 1 and 5 mg groups, respectively; levels that were slightly higher than in adult patients with T2D that were most likely caused by higher plasma DPP-4 concentrations in the study population. There were no drug-related adverse events during treatment with either dose of linagliptin.Linagliptin was well tolerated and induced dose-dependent DPP-4 inhibition that was accompanied by corresponding reductions in HbA1c and FPG levels in young people with T2D. The results are consistent with the clinical efficacy and safety profile that have been reported for linagliptin in adult patients with T2D, favoring linagliptin 5 mg over 1 mg." @default.
• W2770216631 created "2017-12-04" @default.
• W2770216631 creator A5002265183 @default.
• W2770216631 creator A5037184078 @default.
• W2770216631 creator A5039449092 @default.
• W2770216631 creator A5058478381 @default.
• W2770216631 creator A5060236174 @default.
• W2770216631 creator A5060465542 @default.
• W2770216631 creator A5069785394 @default.
• W2770216631 creator A5080190978 @default.
• W2770216631 creator A5081932699 @default.
• W2770216631 creator A5082157064 @default.
• W2770216631 date "2017-11-24" @default.
• W2770216631 modified "2023-09-25" @default.
• W2770216631 title "Randomized, double-blind, placebo-controlled dose-finding study of the dipeptidyl peptidase-4 inhibitor linagliptin in pediatric patients with type 2 diabetes" @default.
• W2770216631 cites W1538553036 @default.
• W2770216631 cites W1887007488 @default.
• W2770216631 cites W2060124483 @default.
• W2770216631 cites W2069122784 @default.
• W2770216631 cites W2074142099 @default.
• W2770216631 cites W2102966941 @default.
• W2770216631 cites W2120251152 @default.
• W2770216631 cites W2128766821 @default.
• W2770216631 cites W2133244310 @default.
• W2770216631 cites W2134625491 @default.
• W2770216631 cites W2140480989 @default.
• W2770216631 cites W2142009487 @default.
• W2770216631 cites W2163251867 @default.
• W2770216631 cites W2168052502 @default.
• W2770216631 cites W2176173337 @default.
• W2770216631 cites W2279296804 @default.
• W2770216631 cites W2296171776 @default.
• W2770216631 cites W2606106417 @default.
• W2770216631 doi "https://doi.org/10.1111/pedi.12616" @default.
• W2770216631 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29171139" @default.
• W2770216631 hasPublicationYear "2017" @default.
• W2770216631 type Work @default.
• W2770216631 sameAs 2770216631 @default.
• W2770216631 citedByCount "11" @default.
• W2770216631 countsByYear W27702166312020 @default.
• W2770216631 countsByYear W27702166312021 @default.
• W2770216631 countsByYear W27702166312022 @default.
• W2770216631 countsByYear W27702166312023 @default.
• W2770216631 crossrefType "journal-article" @default.
• W2770216631 hasAuthorship W2770216631A5002265183 @default.
• W2770216631 hasAuthorship W2770216631A5037184078 @default.
• W2770216631 hasAuthorship W2770216631A5039449092 @default.
• W2770216631 hasAuthorship W2770216631A5058478381 @default.
• W2770216631 hasAuthorship W2770216631A5060236174 @default.
• W2770216631 hasAuthorship W2770216631A5060465542 @default.
• W2770216631 hasAuthorship W2770216631A5069785394 @default.
• W2770216631 hasAuthorship W2770216631A5080190978 @default.
• W2770216631 hasAuthorship W2770216631A5081932699 @default.
• W2770216631 hasAuthorship W2770216631A5082157064 @default.
• W2770216631 hasBestOaLocation W27702166311 @default.
• W2770216631 hasConcept C111113717 @default.
• W2770216631 hasConcept C112705442 @default.
• W2770216631 hasConcept C126322002 @default.
• W2770216631 hasConcept C126894567 @default.
• W2770216631 hasConcept C134018914 @default.
• W2770216631 hasConcept C142724271 @default.
• W2770216631 hasConcept C156490143 @default.
• W2770216631 hasConcept C168563851 @default.
• W2770216631 hasConcept C197934379 @default.
• W2770216631 hasConcept C203092338 @default.
• W2770216631 hasConcept C204787440 @default.
• W2770216631 hasConcept C27081682 @default.
• W2770216631 hasConcept C2777180221 @default.
• W2770216631 hasConcept C2777538456 @default.
• W2770216631 hasConcept C2778375690 @default.
• W2770216631 hasConcept C2778763485 @default.
• W2770216631 hasConcept C2780031085 @default.
• W2770216631 hasConcept C555293320 @default.
• W2770216631 hasConcept C71924100 @default.
• W2770216631 hasConcept C90924648 @default.
• W2770216631 hasConcept C98274493 @default.
• W2770216631 hasConceptScore W2770216631C111113717 @default.
• W2770216631 hasConceptScore W2770216631C112705442 @default.
• W2770216631 hasConceptScore W2770216631C126322002 @default.
• W2770216631 hasConceptScore W2770216631C126894567 @default.
• W2770216631 hasConceptScore W2770216631C134018914 @default.
• W2770216631 hasConceptScore W2770216631C142724271 @default.
• W2770216631 hasConceptScore W2770216631C156490143 @default.
• W2770216631 hasConceptScore W2770216631C168563851 @default.
• W2770216631 hasConceptScore W2770216631C197934379 @default.
• W2770216631 hasConceptScore W2770216631C203092338 @default.
• W2770216631 hasConceptScore W2770216631C204787440 @default.
• W2770216631 hasConceptScore W2770216631C27081682 @default.
• W2770216631 hasConceptScore W2770216631C2777180221 @default.
• W2770216631 hasConceptScore W2770216631C2777538456 @default.
• W2770216631 hasConceptScore W2770216631C2778375690 @default.
• W2770216631 hasConceptScore W2770216631C2778763485 @default.
• W2770216631 hasConceptScore W2770216631C2780031085 @default.
• W2770216631 hasConceptScore W2770216631C555293320 @default.
• W2770216631 hasConceptScore W2770216631C71924100 @default.
• W2770216631 hasConceptScore W2770216631C90924648 @default.
• W2770216631 hasConceptScore W2770216631C98274493 @default.
• W2770216631 hasFunder F4320310441 @default.

• next